Prima Biomed in trading halt

By Tim Dean
Tuesday, 17 November, 2009

Cancer treatment specialist pharmceutical company, Prima Biomed (ASX:PRR), has requested a trading halt on its shares until November 19 pending an announcement regarding the development its oral vaccine for cervical cancer.

Prima Biomed's flagship product is CVac, which is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of ovarian cancer.

Prima Biomed has had a stellar year on the markets. It began the year around $0.005 and rose around 3,200% to its current price.

Prima Biomed shares were last trading at 16.5c.

Content from other channels on our network

Orica cuts particle emissions from Kooragang Island site by 95%

Custom Denning achieves first pantograph fast-charging electric bus

Air-gapped networks give a false sense of security

BHP strengthens partnership with ABB

Seamless modular I/O integration

SA project uses Cement Australia's low-carbon tech

Data centres working to use water responsibly

Orica cuts particle emissions from Kooragang Island site by around 95%

CSIRO's new facility for printed flexible solar techology

Driving change: how electric vehicles are fuelling Australia's sustainable businesses

HNECC PHN installs preventive health service station

Burnet, Atomo to jointly develop active syphilis self-test

My Health Record: ADHA seeks industry input on support, maintenance

Monash, Optiscan partner to develop AI-powered endoscopes

Review proposes major health system changes

Prima Biomed in trading halt

Defective sperm doubles pre-eclampsia risk in IVF patients

Free meningococcal B vaccines coming to the NT

Mouth bacteria linked to increased head and neck cancer risk

Content from other channels on our network